UNSPSC 51314319: Brompheniramine/dextromethorphan/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314319 Brompheniramine/dextromethorphan/phenylpropanolamine is a Commodity code that classifies combination over-the-counter cold and allergy medications, though recent state and local opportunities tagged under this code reflect a broader procurement pattern centered on pharmacy benefit programs, drug distribution networks, and opioid-response pharmaceuticals. State and local governments soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent the active buyers in recent opportunities, with procurement focused on naloxone distribution, direct-to-manufacturer prescription programs, and generic pharmaceutical sourcing through wholesaler networks rather than the specific formulation the code nominally describes.

Recent activity appears concentrated in Florida and Texas, with multistate cooperative purchasing reaching additional jurisdictions including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (IFB issued June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to the county community health building), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products with July 1, 2026 effectiveness and a two-year initial term). The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) explored direct-to-manufacturer prescription fulfillment capabilities as a preliminary market-intelligence step ahead of formal procurement. These opportunities indicate that state and local governments under this code are actively structuring pharmacy benefit programs through cooperative vehicles and direct vendor relationships, with emphasis on compliance, wholesaler integration, and cost management rather than procurement of the specific combination medication the code nominally identifies.